🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,153 results for “Ou” Clear

  1. White opaque capsule filled with a white to off- white powder, eRapa

    Biodexa Pharmaceuticals Plc

    Familial adenomatous polyposis (FAP)

    phase 3 small molecule active

    1 trial

  2. XEOMIN 100 unités, poudre pour solution injectable

    Pari Pharma GmbH

    PANCREATIC FISTULA

    phase 3 small molecule active

    1 trial

  3. XEOMIN 200 jednotek prášek pro injekční roztok, XEOMIN, 200 jednostek, proszek do sporządzania roztworu do wstrzykiwań, XEOMEEN 200 eenheden poeder voor oplossing voor injectie, XEOMIN 200 egység por oldatos injekcióhoz, XEOMIN 200 jednotiek prášok na injekčný roztok, XEOMIN 200 unidades polvo para solución inyectable, XEOMEEN 200 unités poudre pour solution injectable, XEOMIN 200 Einheiten Pulver zur Herstellung einer Injektionslösung, XEOMIN 200 unités, poudre pour solution injectable, XEOMIN, 200 unità,

    Merz Pharmaceuticals GmbH

    Lower limb spasticity

    phase 3 small molecule active

    1 trial

  4. XEOMIN 200 unités, poudre pour solution injectable, Placebo of Xeomin 200 U

    Pari Pharma GmbH

    Adult patients with indication for conventional cardiac surgery (CABG, aortic replacement, or ascending aorta surgery)

    phase 3 small molecule active

    1 trial

  5. Xevinapant (Debio 1143)

    Serono Europe Limited

    Squamous Cell Carcinoma of the Head and Neck

    phase 3 small molecule terminated

    1 trial

  6. YERVOY 5 mg/ml concentrate for solution for infusion, OPDIVO 10 mg/mL concentrate for solution for infusion., YERVOY 5 mg/ml concentrate for solution for infusion, Irinotecan Bendalis 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, FLUOROURACIL, OPDIVO 10 mg/mL concentrate for solution for infusion., Avastin 25 mg/ml concentrate for solution for infusion, DISODIUM FOLINATE

    Bristol-Myers Squibb Australia Pty Ltd

    Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient Metastatic Colorectal Cancer (dMMR)

    phase 3 small molecule active

    1 trial

  7. Zanubrutinib

    BEONE MEDICINES AUS PTY LTD

    Primary Membranous Nephropathy

    phase 3 small molecule active

    1 trial

  8. Zodasiran

    Arrowhead Pharmaceuticals Ireland Limited

    Homozygous Familial Hypercholesterolemia

    phase 3 small molecule active

    1 trial

  9. a compound glutamine capsule

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Mucositis

    phase 3 small molecule active

    1 trial

  10. a compound glutamine capsule/a compound glutamine capsule simulated placebo

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Mucositis

    phase 3 small molecule active

    1 trial

  11. alprazolam, Placebo matching Staccato® alprazolam and without active substance

    Lacuna Pharma Pty Ltd

    Treatment of stereotypical prolonged seizure

    phase 3 small molecule active

    1 trial

  12. azithromycin SR (Zithromax; compound: CP-62,993)

    Pfizer

    Bronchitis, Chronic

    phase 3 small molecule completed

    1 trial

  13. batch 1 of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) (MCV4)

    CanSino Biologics

    Meningococcal Meningitis

    phase 3 mab active

    1 trial

  14. bevacizumab

    Outlook Therapeutics NL B. V.

    Neovascular Age-related Macular Degeneration

    phase 3 mab completed

    1 trial

  15. bevacizumab

    Outlook Therapeutics NL B. V.

    Age-related Macular Degeneration

    phase 3 mab active

    4 trials

  16. bivalent enterovirus vaccine (Vero cell), inactivated

    Sinovac Research and Development Co.,

    Hand, Foot, and Mouth Disease（HFMD)

    phase 3 mab active

    1 trial

  17. brivaracetam, -, -, brivaracetam, -, brivaracetam, Placebo matching < brivaracetam oral solution> and without active substance

    Lacuna Pharma Pty Ltd

    Childhood Absence Epilepsy Juvenile Absence Epilepsy

    phase 3 small molecule active

    1 trial

  18. dabigatran etexilate

    Boehringer Ingelheim

    Venous Thromboembolism

    phase 3 small molecule completed

    1 trial

  19. dupilumab

    Regeneron UK Limited

    Bullous Pemphigoid

    phase 3 small molecule completed

    1 trial

  20. eRapa (encapsulated rapamycin)

    Biodexa Pharmaceuticals Plc

    Familial Adenomatous Polyposis (FAP)

    phase 3 small molecule active

    1 trial

  21. edoxaban tosylate(DU-176b)

    Daiichi Sankyo

    Venous Thromboembolism

    phase 3 small molecule completed

    1 trial

  22. efgartigimod PH20 SC

    argenx

    Bullous Pemphigoid

    phase 3 mab completed

    1 trial

  23. erlotinib

    Hoffmann-La Roche

    Non-Squamous Non-Small Cell Lung Cancer

    phase 3 small molecule completed

    1 trial

  24. evinacumab

    Regeneron UK Limited

    Homozygous Familial Hypercholesterolemia

    phase 3 small molecule completed

    3 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources